VKTX Initiates Phase 3 Study on Obesity Candidate VK2735
Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $28.59, representing a -1.26% change from its previous close.
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Viking Therapeutics: Buy It For The Future And Ignore The Noise
VKTX remains a speculative, high-risk/reward play, with its future hinging on successful Phase III trial results for its obesity drug pipeline. The company's strong cash position and recent manufacturing partnerships support its path toward commercialization, despite expected negative free cash flow through FY2028. VKTX's diversified pipeline, including NAFLD and rare disease prospects, provides some downside protection as it awaits pivotal clinical milestones.
Viking Therapeutics: Weight-Loss Story Remains Intact
Viking Therapeutics remains a promising weight-loss drug biotech due to the enrollment of new promising trials. The weight-loss sector's momentum has faded some, but Eli Lilly and Novo Nordisk have still generated substantial value for shareholders. Viking Therapeutics has upcoming catalysts, including late-July Phase 2 oral data and Phase 3 injectable trial enrollment, potentially driving significant upside in the stock.
Viking Therapeutics: A High Potential Biotech Play With Manageable Risks
Viking targets massive, validated markets with GLP-1/GIP and THR-β agonists, offering injectable and oral alternatives with promising Phase 2/3 results. Positioned as a second-line, tolerable, patient-friendly treatment in an established space with significant addressable market size. Compared to some other binary bets in big pharma, Viking offers leaner operations, lower complexity, faster trial execution, and less execution risk.
Viking Therapeutics: Near-Term Catalysts And Competitor Readouts
VKTX's VENTURE-Oral study of VK2735 has completed enrollment, with a readout set for H2'25. The company's phase 3 program on subcutaneous VK2735 is getting underway, although given it will contain thousands of patients, a readout isn't a near-term prospect. VKTX will evaluate once-monthly maintenance dosing of VK2735 in 2025, which could allow it to confirm it can compete with the likes of agents from AMGN and MTSR.
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April
One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics' (VKTX 0.32%) stock in April.
Why Viking Therapeutics Stock Was Victorious This Week
Viking Therapeutics (VKTX 2.85%), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was a winning stock this week. Over the course of the past five trading days, its price rose by almost 18%, according to data compiled by S&P Global Market Intelligence.
Where Will Viking Therapeutics Be in 3 Years?
The pharmaceutical and biotechnology business tends to be about hitting home runs more than just getting on base. A highly successful drug, sometimes referred to as a blockbuster, can build up a small developer into a mainstream competitor.
1 Beaten-Down Stock to Buy and Hold for 10 Years
Viking Therapeutics (VKTX 3.44%) was one of the hottest biotech stocks of 2024; its shares soared last year following excellent clinical progress. However, things have been very different in 2025, at least so far: Its stock is down by 35% year to date due to a combination of factors.
